Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 15

1.

The mechanism of action of the Pseudomonas aeruginosa-encoded type III cytotoxin, ExoU.

Sato H, Frank DW, Hillard CJ, Feix JB, Pankhaniya RR, Moriyama K, Finck-Barbançon V, Buchaklian A, Lei M, Long RM, Wiener-Kronish J, Sawa T.

EMBO J. 2003 Jun 16;22(12):2959-69.

2.

Multiple domains are required for the toxic activity of Pseudomonas aeruginosa ExoU.

Finck-Barbançon V, Frank DW.

J Bacteriol. 2001 Jul;183(14):4330-44.

3.

Biological effects of Pseudomonas aeruginosa type III-secreted proteins on CHO cells.

Vallis AJ, Finck-Barbançon V, Yahr TL, Frank DW.

Infect Immun. 1999 Apr;67(4):2040-4.

4.
5.

Pseudomonas aeruginosa invasion and cytotoxicity are independent events, both of which involve protein tyrosine kinase activity.

Evans DJ, Frank DW, Finck-Barbançon V, Wu C, Fleiszig SM.

Infect Immun. 1998 Apr;66(4):1453-9.

6.

ExoU expression by Pseudomonas aeruginosa correlates with acute cytotoxicity and epithelial injury.

Finck-Barbançon V, Goranson J, Zhu L, Sawa T, Wiener-Kronish JP, Fleiszig SM, Wu C, Mende-Mueller L, Frank DW.

Mol Microbiol. 1997 Aug;25(3):547-57.

7.

Preferential processing of the S1 subunit of pertussis toxin that is bound to eukaryotic cells.

Finck-Barbançon V, Barbieri JT.

Mol Microbiol. 1996 Oct;22(1):87-95.

PMID:
8899711
8.

Panton-Valentine leucocidin and gamma-hemolysin from Staphylococcus aureus ATCC 49775 are encoded by distinct genetic loci and have different biological activities.

Prévost G, Cribier B, Couppié P, Petiau P, Supersac G, Finck-Barbançon V, Monteil H, Piemont Y.

Infect Immun. 1995 Oct;63(10):4121-9.

9.

Functional domains of Pseudomonas aeruginosa exoenzyme S.

Knight DA, Finck-Barbançon V, Kulich SM, Barbieri JT.

Infect Immun. 1995 Aug;63(8):3182-6.

10.

ADP-ribosylation of alpha i3C20 by the S1 subunit and deletion peptides of S1 of pertussis toxin.

Finck-Barbançon V, Barbieri JT.

Biochemistry. 1995 Jan 24;34(3):1070-5.

PMID:
7827022
12.

Pore formation by a two-component leukocidin from Staphylococcus aureus within the membrane of human polymorphonuclear leukocytes.

Finck-Barbançon V, Duportail G, Meunier O, Colin DA.

Biochim Biophys Acta. 1993 Oct 20;1182(3):275-82.

PMID:
8399361
13.

A structurally novel staphylococcal protein A from the V8 strain.

Finck-Barbançon V, Prevost G, Mazurier I, Piemont Y.

FEMS Microbiol Lett. 1992 Feb 1;70(1):1-8.

PMID:
1577250
14.

Staphylococcus aureus leukocidin: a new virulence factor in cutaneous infections? An epidemiological and experimental study.

Cribier B, Prévost G, Couppie P, Finck-Barbançon V, Grosshans E, Piémont Y.

Dermatology. 1992;185(3):175-80.

PMID:
1446082
15.

Improved purification of leukocidin from Staphylococcus aureus and toxin distribution among hospital strains.

Finck-Barbançon V, Prévost G, Piémont Y.

Res Microbiol. 1991 Jan;142(1):75-85.

PMID:
2068381

Supplemental Content

Loading ...
Support Center